Stem Cell Clinic

Genetic influences on viral-induced cytokine responses in the lung – DocWire News

By Induced Pluripotent Stem Cells

This article was originally published here

Mucosal Immunol. 2020 Nov 12. doi: 10.1038/s41385-020-00355-6. Online ahead of print.

ABSTRACT

Infection with respiratory viruses such as influenza, respiratory syncytial virus and coronavirus provides a difficult immunological challenge for the host, where a balance must be established between controlling viral replication and limiting damage to the delicate lung structure. Although the genetic architecture of host responses to respiratory viral infections is not yet understood, it is clear there is underlying heritability that influences pathogenesis. Immune control of virus replication is essential in respiratory infections, but overt activation can enhance inflammation and disease severity. Cytokines initiate antiviral immune responses but are implicated in viral pathogenesis. Here, we discuss how host genetic variation may influence cytokine responses to respiratory viral infections and, based on our current understanding of the role that cytokines play in viral pathogenesis, how this may influence disease severity. We also discuss how induced pluripotent stem cells may be utilised to probe the mechanistic implications of allelic variation in genes in virus-induced inflammatory responses. Ultimately, this could help to design better immune modulators, stratify high risk patients and tailor anti-inflammatory treatments, potentially expanding the ability to treat respiratory virus outbreaks in the future.

PMID:33184476 | DOI:10.1038/s41385-020-00355-6

See more here:
Genetic influences on viral-induced cytokine responses in the lung - DocWire News

Japanese and U.S. astronauts arrive at ISS in SpaceX ship – The Japan Times

By Induced Pluripotent Stem Cells

Cape Canaveral, Florida The commercially developed SpaceX Crew Dragon ship carrying a group of astronauts, including Japan's Soichi Noguchi, successfully docked with the International Space Station on Monday following its liftoff from NASA's space center a day earlier.

Three NASA astronauts Michael Hopkins, Victor Glover and Shannon Walker and Noguchi of the Japan Aerospace Exploration Agency, made up the crew that will begin a six-month mission at the orbiting laboratory.

"Oh, what a good voice to hear, space station astronaut Kate Rubins called out when the Dragon's commander, Hopkins, first made radio contact. The linkup occurred 422 kilometers above the U.S. state of Idaho.

The second manned flight to the ISS by the Crew Dragon capsule, developed by the U.S. company Space Exploration Technologies Corp., followed a test flight earlier this year with two NASA astronauts.

Noguchi, 55, became the first non-American astronaut to be ferried by NASA's first-ever certified commercial human spacecraft system.

Japan Aerospace Exploration Agency (JAXA) astronaut Soichi Noguchi waves as the crew of a SpaceX Falcon 9 rocket departs to the launchpad for the first operational NASA commercial crew mission at Kennedy Space Center in Cape Canaveral, Florida, on Sunday. | REUTERS

He is a veteran astronaut with experience from two previous space missions, having been aboard the Space Shuttle Discovery in 2005 and a Russian Soyuz spacecraft for a 161-day stay on the ISS between 2009 and 2010.

During his present stay on the ISS through April, Noguchi is expected to carry out experiments involving iPS cells, or induced pluripotent stem cells, which can be converted into any type of cell in the body, according to JAXA.

The SpaceX system is expected to serve as a successor to NASA's Space Shuttle program that was in service for 30 years through 2011, its development ending the subsequent years of reliance on the Russian Soyuz vehicle as the sole means of accessing the ISS.

Seats in the Soyuz have cost NASA around $80 million or more each in recent years, according to a 2019 report by the U.S. space agency's Office of Inspector General. NASA hopes to reduce crew transportation costs through commercial systems developed in the United States.

The latest development is welcome news for Japan, which also has had to rely on the Soyuz vehicle to send its astronauts to the ISS.

NASA officials have highlighted the importance of sending more astronauts to the ISS, which increases the capacity for scientific research in space.

The arrival of the four astronauts raises the total number of crew members aboard the ISS to seven. Permanent human occupancy of the station began in November 2000.

See the rest here:
Japanese and U.S. astronauts arrive at ISS in SpaceX ship - The Japan Times

AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update – BioSpace

By Induced Pluripotent Stem Cells

Nov. 16, 2020 21:05 UTC

ALAMEDA, Calif.--(BUSINESS WIRE)-- AgeX Therapeutics, Inc.. (AgeX; NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat human diseases to increase healthspan and combat the effects of aging, reported financial and operating results for the third quarter ended September 30, 2020.

Q3 Highlights

This quarter, we continued to build upon our licensing and collaboration model through our new agreement with ImStem that provides us an avenue for participating financially in potential treatments for COVID-19 and acute respiratory distress syndrome or ARDS. Since the first of the year, AgeX has entered into six agreements that could lead to the development of new cell therapies by our licensees and collaborators, which utilize our core technologies and cell lines with potential future income streams to AgeX, said Greg Bailey M.D., Chairman of AgeX. In addition, expansion of our agreement related to ESI clinical-grade pluripotent stem cell lines will now allow us independence to build ESI cell lines as a to-go-to source for deriving cell based therapeutics across the industry.

Liquidity and Capital Resources

AgeX is in need of additional capital to finance its operations. On March 30, 2020, AgeX entered into a Secured Convertible Facility Agreement (the New Loan Agreement) with Juvenescence Limited pursuant to which AgeX may borrow funds from time to time. As of November 16, 2020, AgeX has borrowed $5.5 million and may draw additional funds from time to time subject to Juvenescences discretion, prior to the contractual repayment date on March 30, 2023. AgeX may not draw down more than $1.0 million in any single draw. More information about the New Loan Agreement can be found in AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for the periods ended March 31, 2020, June 30, 2020, and September 30, 2020 filed with the Securities and Exchange Commission on March 30, 2020, May 14, 2020, August 14, 2020, and November 16, 2020, respectively.

Going Concern Considerations

As required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), AgeX evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date its financial statements are issued. Based on AgeXs most recent projected cash flows, and considering that loans from Juvenescence under the New Loan Agreement will be subject to Juvenescences discretion, AgeX believes that its cash and cash equivalents, the remaining $2.5 million available under the New Loan Agreement and reduction in staff in May 2020 would not be sufficient to satisfy its anticipated operating and other funding requirements for the twelve months following the filing of AgeXs Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2020. These factors raise substantial doubt regarding the ability of AgeX to continue as a going concern.

Third Quarter 2020 Operating Results

Revenues: Total revenues for the third quarter of 2020 were $434,000 as compared with $411,000 for the third quarter of 2019. AgeX revenues are primarily generated from subscription and advertising revenues from the GeneCards online database through its subsidiary LifeMap Sciences, Inc. Revenues in 2020 also included approximately $40,000 of allowable expenses under AgeXs research grant from the NIH. Revenues from that grant were $41,000 in the same period in 2019.

Operating expenses: Operating expenses for the three months ended September 30, 2020 were $2.8 million as compared to $3.6 million for the same period in 2019. Operating expenses are comprised of research and development expense and general and administrative expenses. On an as-adjusted basis, operating expenses for the three months ended September 30, 2020 were $2.3 million as compared to $3.0 million for the same period in 2019.

The reconciliation between GAAP and non-GAAP operating expenses is provided in the financial tables included with this earnings release.

Research and development expenses were $0.8 million during the three months ended September 30, 2020, a $0.6 million decrease from $1.4 million during the same period in 2019. The decrease was primarily attributable to the layoff of 11 research and development personnel in May 2020 and the elimination of shared services payments to Lineage Cell Therapeutics, Inc. (Lineage) with the termination of our Shared Facilities and Services Agreement on September 30, 2019.

General and administrative expenses decreased by $0.3 million to $1.9 million during the three months ended September 30, 2020 from $2.2 million during the same period in 2019 despite an increase in head count resulting from the employment of AgeXs own finance team commencing in October 1, 2019. These increases were offset by a decrease in noncash stock-based compensation expense, travel and related expenses with the shelter in place mandates since March 15, 2020 resulting from the COVID-19 pandemic, and the elimination of shared facilities and services fees from Lineage following the termination of the Shared Facilities and Services Agreement on September 30, 2019.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics to treat human diseases to increase healthspan and combat the effects of aging. AgeXs PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. HyStem is AgeXs delivery technology to stably engraft PureStem or other cell therapies in the body. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT PAR VALUE AMOUNTS)

September 30, 2020

December 31, 2019

(Unaudited)

ASSETS

CURRENT ASSETS

Cash and cash equivalents

$

1,107

$

2,352

Accounts and grants receivable, net

241

363

Prepaid expenses and other current assets

581

1,339

Total current assets

1,929

4,054

Excerpt from:
AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update - BioSpace

Asymmetrex Publishes the First Report of Immortal DNA Strands in Human Stem Cells – PR Web

By Stem Cell Medicine

Example of a tissue stem cell (left) holding on to its immortal DNA strands after dividing to produce a maturing tissue cell (right).

BOSTON (PRWEB) November 18, 2020

What does it mean for multiplying cells in the body to be immortal? The cell DNA is being replicated over and over again while being divided equally between new cells produced by cell divisions. All the new cell components produced by the DNA code are mixing with the old cell components and being divided between the new cells. So, every cell is a new cell. There is nothing really immortal about any of them. Right?

Not quite. Stem cells responsible for renewing other mature body cells are different. For a long time, tissue cell scientists had a somewhat nebulous idea that stem cells had a special longevity in organs and tissues that they were immortal cells, lasting for as long as the human lifespan. However, no one had a molecular concept for this idea of stem cell immortality until John Cairns, a pioneer of DNA replication, started thinking about DNA mutations and cancer in the 1970s.

Cairns predicted that stem cells did something unique with their DNA code. He said they held on to one strand of every one of their many chromosomes and never shared those DNA strands with the tissue cells they renewed. Cairns called these immortal DNA strands. Cairns argued that immortal DNA strands must exist to explain how immortal stem cells avoid higher cancer rates.

Asymmetrex director James Sherley calls the immortal strand hypothesis the Carpenters Rule for stem cells. Good carpenters avoid creeping measurement errors by using a ruler or the same piece of wood to measure duplicates. Too many DNA duplication errors in cells make them cancerous. Cairns proposed that stem cells were smart carpenters, keeping and using the same DNA strands for making their many replicate copies over the human lifespan.

Prior to Asymmetrexs new report, published in a special issue of the peer-reviewed journal Symmetry, there were many publications on the presence of immortal DNA strands in stem cells of other species, including molds, plants, insects, and mice. Low levels of immortal DNA strands were also reported for human cancer cells.

The new report from Asymmetrex describes the presence of immortal DNA strands in human liver stem cells. The SACK-Xs 12(3) stem cells used in the study were developed more than a decade earlier using Asymmetrexs patented SACK tissue stem cell expansion technology. SACK-Xs 12(3) human liver stem cells are distributed for research by Kerafast. They are the first and only commercial human tissue stem cell product supplied with their stem cell-specific dosage, certified by Asymmetrex.

The new report brings an important closure for an ingenious scientific deduction by a remarkable scientist, John Cairns, recently deceased. Now that normal human tissue stem cells are confirmed to have immortal DNA strands, scientists can get on with the business of leveraging this knowledge to a better understanding of tissue stem cells for improving human health.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The companys U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation therapies and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

Share article on social media or email:

Follow this link:
Asymmetrex Publishes the First Report of Immortal DNA Strands in Human Stem Cells - PR Web

Study reveals how smoking worsens SARS-CoV-2 infection in the airways – UCLA Newsroom

By Stem Cell Medicine

UCLA researchers using a model of airway tissue created from human stem cells have pinpointed how smoking cigarettes causes more severe infection by SARS-CoV-2, the virus that causes COVID-19, in the airways of the lungs.

The study, led by scientists at theEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLAand published in Cell Stem Cell, will help researchersbetter understand COVID-19 risks for smokers and could inform the development of new therapeutic strategies to help reduce smokers chances of developing severe disease.

Cigarette smoking is one of the most common causes of lung diseases, including lung cancer and chronic obstructive pulmonary disease, and most demographic studies of COVID-19 patients have indicated that current smokers are at increased risk of severe infection and death. But the reasons why have not been entirely clear.

To help understand how smoking affects SARS-CoV-2 infection on a cellular and molecular level, Dr. Brigitte Gomperts partnered with co-senior authors Vaithilingaraja Arumugaswami, an associate professor of molecular and medical pharmacology, and Kathrin Plath, a professor of biological chemistry, to recreate what happens when the airways of a current smoker are infected with SARS-CoV-2.

The team utilized a platform known as an airliquid interface culture, which is grown from human airway stem cells and closely replicates how the airways behave and function in humans. The airways, which carry air breathed in from the nose and mouth to the lungs, are the bodys first line of defense against airborne pathogens like viruses, bacteria and smoke.

Our model replicates the upper part of the airways, which is the first place the virus hits, said Gomperts, a professor pulmonary medicine and member of theUCLA Jonsson Comprehensive Cancer Center. This is the part that produces mucus to trap viruses, bacteria and toxins and contains cells with finger-like projections that beat that mucus up and out of the body.

The airliquid interface cultures used in the study were grown from airway stem cells taken from the lungs of five young, healthy, nonsmoking tissue donors. To replicate the effects of smoking, the researchers exposed these airway cultures to cigarette smoke for three minutes per day over four days.

This type of model has been used to study lung diseases for over a decade and has been shown to mimic the changes in the airway that you would see in a person who currently smokes, said Gomperts, who is also vice chair of research in pediatric hematology-oncology at theUCLA Childrens Discovery and Innovation Institute.

Next, the group infected the cultures exposed to cigarette smoke along with identical cultures that had not been exposed with live SARS-CoV-2 virus, and the two groups were compared. In the models exposed to smoke, the researchers saw between two and three times more infected cells.

Digging further, the researchers determined that smoking resulted in more severe SARS-CoV-2 infection, at least in part, by blocking the activity of immune system messenger proteins called interferons. Interferons play a critical role in the bodys early immune response by triggering infected cells to produce proteins to attack the virus, summoning additional support from the immune system, and alerting uninfected cells to prepare to fight the virus. Cigarette smoke is known to reduce the interferon response in the airways.

If you think of the airways like the high walls that protect a castle, smoking cigarettes is like creating holes in these walls, Gomperts said. Smoking reduces the natural defenses and that allows the virus to set in.

Co-first authors of the study are Arunima Purkayastha, Chandani Sen, Gustavo Garcia Jr. and Justin Langerman, all of UCLA.

This work was supported by the National Institutes of Health, the UCLA Medical Scientist Training Program, aUCLA David Geffen School of MedicineBroad Stem Cell Research Center COVID-19 Research Award, the California Institute for Regenerative Medicine, theUCLA Clinical and Translational Science Institute (supported by National Institutes of Healths National Center for Advancing Translational Sciences), the Tobacco-Related Disease Research Program, and the Ablon Scholars Program at the UCLA Jonsson Comprehensive Cancer Center and UCLA Broad Stem Cell Research Center.

Read the rest here:
Study reveals how smoking worsens SARS-CoV-2 infection in the airways - UCLA Newsroom

Stem Cells Market Detailed Analysis by On-going Trends, Prominent Size, Share, Sales and Forecast to 2025 – PRnews Leader

By Stem Cell Medicine

A succinct analysis of market size, regional growth and revenue projections for the coming years is presented in GlobalStem Cells Marketreport. The study further sheds light on major issues and the new growth strategies implemented by manufacturers that are part ofcompetitive landscape of the studied market.Thereport offers key trends, investment opportunities and drivers in Global Stem Cells Marketwith the latest market intelligence by adopting primary and secondary research methods. It also includes strategies adopted in the context of acquisitions and mergers, and business footprint extensions.

In order to provide more exactmarket forecast, the report comprises a complete research study and analysis ofCOVID-19 impact on the Global Stem Cells market. It also considers the strategies that can be adopted to deal with the situation.

Get sample [emailprotected] https://www.kdmarketinsights.com/sample/3333

Competitive Landscape and Stem Cells Market Share Analysis:

The competitive landscape of the Stem Cells market provides data about the players operating in the studied market. The report includes a detailed analysis and statistics onprice, revenue and market share of the playersfor the period 2020-2025. The major players covered are as follows:

Thermo Fisher Scientific Inc.

Cellular Engineering Technologies Inc

Qiagen N.V

Sigma Aldrich Corporation

Becton, Dickinson and Company

Miltenyi Biotec

International Stem Cell Corporation

Stem Cell Technologies Inc.

Pluristem Therapeutics Inc

Medtronic, Inc

Zimmer Holdings, Inc.

Bio Time Inc

Zimmer Holdings, Inc

Orthofix, Inc.

Osiris Therapeutics Inc

Others Prominent Players

Key segments covered:

By Product

Adult Stem Cells

Neural Stem Cells

Hematopoietic Stem Cells

Mesenchymal Stem Cells

Umbilical Cord Stem Cells

Epithelial Stem cells and Skin Stem Cells

Others

Human Embryonic Stem Cells

Induced Pluripotent Stem Cells

Others

By Application

Regenerative Medicine

Neurology Regenerative Medicine

Oncology Regenerative Medicine

Myocardial Infraction Regenerative Medicine

Diabetes Regenerative Medicine

Hematology & Immunology Regenerative Medicine

Orthopedics Regenerative Medicine

Other Regenerative Medicine

Drug Discovery and Development

Other Applications

By Technology

Cell Acquisition

Bone Marrow Harvest

Umbilical Blood Cord

Apheresis

Others

Cell Production

Therapeutic Cloning

In-vitro Fertilization

Cell Culture

Isolation

Cryopreservation

Expansion and Sub-Culture

By End-User

Biopharmaceutical

Biotechnology Industry

Research Institutes

By Treatment Type

Allogeneic Stem Cell Therapy

Auto logic Stem Cell Therapy

Syngeneic Stem Cell Therapy

By Banking Type

Public

Private

By Region:

North America (U.S. & Canada)

Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand, and Rest of Asia Pacific)

Latin America (Brazil, Mexico, and Rest of Latin America)

Middle East & Africa (GCC, North Africa, South Africa, and Rest of Middle East & Africa)

Get Complete Research Report with [emailprotected]https://www.kdmarketinsights.com/product/3333/stem-cells-market

Some Important Highlights from the Report include:

Market CAGR during the 2020-2025 forecast period.

Comprehensive analysis on factors that will speed up the growth of Stem Cells marketover the next five years.

Precise estimates about the market size of global Stem Cells market and itscontribution to the parent market.

Precise forecasts for future developments in the Stem Cells industry and shifts in consumer behavior.

The growth of the Stem Cells Market across the Americas, APAC, Europe and MEA.

A detailed analysis of the industry competition and quantitative data on various vendors.

Comprehensive information on variables that will impede the growth of Stem Cells companies.

The Following are the Key Features of Global Stem Cells Market Report:

Market Overview, Industry Development, Market Maturity, PESTLE Analysis, Value Chain Analysis

Growth Drivers and Barriers, Market Trends & Market Opportunities

Porters Five Forces Analysis & Trade Analysis

Market Forecast Analysis for 2020-2025

Market Segments by Geographies and Countries

Market Segment Trend and Forecast

Market Analysis and Recommendations

Price Analysis

Key Market Driving Factors

Stem Cells Market Company Analysis: Company Market Share & Market Positioning, Company Profiling, Recent Industry Developments etc.

Why Choose KD Market Insights?

Provides accurate data and best-in class solutions to our clients.

Offers optimal market predictions and analysis of the business.

Ensures that clients gain unmatched competitive advantage, builds more competent organizations, and ensures enduring outcomes.

Get Discount [emailprotected]https://www.kdmarketinsights.com/discount/3333

About Us:

Go here to read the rest:
Stem Cells Market Detailed Analysis by On-going Trends, Prominent Size, Share, Sales and Forecast to 2025 - PRnews Leader

Cell Expansion Market Analysis, COVID-19 Impact,Outlook, Opportunities, Size, Share Forecast and Supply Demand 2021-2027|Trusted Business Insights -…

By Stem Cell Medicine

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Cell Expansion market.

Trusted Business Insights presents an updated and Latest Study on Cell Expansion Market 2020-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Cell Expansion market during the forecast period (2020-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Cell Expansion Market 2020 and Forecast 2021-2027 Includes Business Impact Analysis of COVID-19

Report Overview: Cell Expansion Market

The global cell expansion market size was estimated at USD 18.1 billion in 2020 is expected to register a compound annual growth rate (CAGR) of 8.3% over the forecast period 2021-2027. Increase in usage of automated solutions in cell expansion applications is one of the market drivers. Automated systems minimize the manpower and cost incurred during the production of Cell Therapy Products (CTP), gene therapies, and other biologics; leading to robust and reliable processes.

Key players engaged in CTP development are expanding their product line to suffice the significant rise in the global demand for these therapy products. For instance, in March 2019, Lonza introduced a comprehensive portfolio of CellBio Services, which includes cell-line expansion and banking services. This solution is designed to fulfill research application requirements, finally accelerating the revenue generation in the market.

The paradigm shift toward Single-Use Systems (SUS) offers substantial production advantages in CTP manufacturing. SUS eliminates concerns of cross-contamination and culture contamination caused due to inappropriate sterilization. SUS also allows the production of CTP with high cell densities as well as offers cost-savings in the long run. Thus, a rise in the adoption of SUS surges the development of CTP, which boosts the market growth.

Cellular therapies are constantly gaining popularity in the life sciences industry. Rise in funding from private & government organizations and initiatives undertaken by them to encourage the development of cellular therapies act as drivers for the market. The International Society for Stem Cell Research is involved in the identification of stem cell-related funding opportunities across biomedical research applications.

Substitution of serum and other incompatible reagents is essential to control the quality of the product in CTP manufacturing. Several research studies have validated that the application of serum-free media controls product quality. Researchers have also developed an optimization platform that integrates high-throughput tools with a differential evolution-based algorithm, which acts as an automated effective optimization strategy for serum-free culture formulations.

Product Insights: Cell Expansion Market

Consumables led the product segment in 2019 and accounted for 46.8% of the overall share. It is estimated to retain its dominant position throughout the forecast years. Availability of a wide range of commercial media and reagent products that are dedicated to specific type of cells contributes to the large revenue share of this segment. In addition, these products are convenient, ready-to-use, and are also available as serum-free formulations.

The instruments segment is expected to register the highest CAGR over the forecast period owing to automation in bioreactors and other expansion platforms to enhance the efficiency of culturing procedures. The advent of automated platforms standardizes the process and facilitates process tracking while reducing the hands-on time; therefore, enables more effective use of the time of skilled personnel.

Continuous commercialization and introduction of automated culturing equipment also drive the revenue generation in the instruments segment. For instance, in March 2019, Hitachi, Ltd. commercialized its automated cell mass culture equipment in Japan. This commercialization allowed manufacture of induced pluripotent stem cells for regenerative medicine applications. Such efforts are expected to accelerate the revenue generation for instruments.

Cell Type Insights: Cell Expansion Market

Mammalian cells segment held the largest revenue share of 58.5% in 2019 and will remain dominant during the forecast period as these culture systems are highly preferred in production of complex protein therapeutics. This is because these systems are pharmacokinetically and functionally relevant to post-translational modifications in humans. Therefore, most of the biopharmaceuticals, including monoclonal antibodies, specific interferons, thrombolytics, and various therapeutic enzymes, are produced using these culture systems.

Differentiated human cells accounted for substantial revenue share as these cells perform a specific function in the body. Differentiated cells, such as fibroblasts, have gained immense importance in the cutaneous wound healing and skin bioengineering, thereby augmenting the segment growth. Moreover, evaluation of 3D Gingival Fibroblast (GF) toroids as a feasible and simple in vitro assay for biomaterial testing has expanded their usage rate.

Human stem cells have gained significant traction and are expected to witness the fastest CAGR from 2020 to 2027. The exponential growth of research in this sector and the huge success of regenerative medicine are among the key factors that can be attributed to the fastest growth rate. Furthermore, implementation of automated, robotic, and closed production systems in the manufacturing of clinical-grade mesenchymal stem cells drives the segment.

Application Insights: Cell Expansion Market

The biopharmaceutical segment captured the largest revenue share of 22.9% in 2019 owing to increase in the approvals of biopharmaceutical products in the past few years. The entry of new biopharmaceutical companies and the proliferation of bioprocessing technologies further drive the development of biopharmaceuticals, which, in turn, boosts the expansion procedures conducted during bio-production.

In addition, single-use technologies are gaining immense traction in manufacturing cellular therapies on a commercial level. The introduction of alternative planar cell expansion technologies, such as compact multi-layer bioreactors, has been witnessed over the years. This sufficed the requirement of closed systems that limits the potential risks associated with contamination and maintains control of a large-scale upstream production and unit production. The vaccine production segment is expected to witness the fastest growth rate during the forecast period due to the expansion of cell-based vaccine production in recent years. The production of these vaccines offers a cost-effective manufacturing solution while accelerating the development process.

End-use Insights: Cell Expansion Market

Biotechnology & biopharmaceutical companies segment held the largest share of 48% in 2019 and will expand further at a significant growth rate. The broadening horizon of cell-based therapeutics in the healthcare industry is one of the major factors contributing to the large share of biopharmaceutical companies. For instance, cellular-based therapies have gained immense popularity in regenerative medicine with constant improvements in injectable cell delivery systems for various clinical applications.

In addition, pharmaceutical & biopharmaceutical companies are also engaged in acquisitions to expand their product portfolio. For instance, in December 2019, Sartorius AG signed an agreement to acquire 50% shares of Biological Industries, an Israeli cell culture media manufacturer. This acquisition expanded the cell culture media portfolio of Sartorius, especially for cellular and gene therapies, regenerative medicine, and other advanced therapies.

Research institutes are anticipated to register the highest CAGR from 2020 to 2027 as researchers are engaged in several studies in the biomedical field. For instance, in April 2019, researchers at the University of Wisconsin, U.S., introduced a new technology for effortless development of the H3N2 vaccine. For this, they developed a new cell line that enhanced the growth of H3N2 for vaccine use. Such research findings are expected to help in introducing new products in this market.

Regional Insights: Cell Expansion Market

North America accounted for the largest share of 43.1% in 2019. The region will retain its leading position over the coming years due to a rise in funding initiatives by the government agencies, which has accelerated the manufacture of stem cells and the development of regenerative medicine and cellular therapy products. This, in turn, drives the demand for cell expansion platforms in this region.

For instance, in October 2019, the FDA and the Medical Technology Enterprise Consortium (MTEC) together provided funding of USD 5.3 million to the Southwest Research Institute (SwRI) (U.S.). The SwRI invested these funds to propagate cells for the development of personalized regenerative medicine. Such investments boost the revenue generation in this region.

Asia Pacific is expected to witness the fastest growth during the forecast period due to increasing efforts laid down by several local pharmaceutical and biotechnology companies to develop and commercialize their cellular therapies. An Indian company, Stempeutics Research Pvt. Ltd., signed an alliance with Kemwell Biopharma in July 2019 for the commercialization of its stem cell-based product, Stempeucel. Such agreements are expected to boost product sales of small- and mid-scale companies.

Key Companies & Market Share Insights: Cell Expansion Market

Key market participants are undertaking several initiatives to expand their market presence and maintain a competitive edge in the space. Moreover, they are involved in collaboration & partnership models, product development, agreements, and business expansion strategies in untapped regions.

For instance, in June 2019, Demcon acquired a share in the Scinus Cell Expansion B.V., a manufacturer of stem cell-based therapy equipment headquartered in the Netherlands. This acquisition helped Scinus to expand its business in the stem cell therapy market. Such growth initiatives are expected to enhance the utilization rate of bioreactors used for culturing stem cells, thereby leading to market growth. Some of the prominent players in the cell expansion market include:

Key companies Profiled: Cell Expansion Market Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Trusted Business Insights has segmented the global cell expansion market report on the basis of product, cell type, application, end use, and region:

Product Outlook (Revenue, USD Million, 2016 2027)

Cell Type Outlook (Revenue, USD Million, 2016 2027)

Application Outlook (Revenue, USD Million, 2016 2027)

End-use Outlook (Revenue, USD Million, 2016 2027)

Looking for more? Check out our repository for all available reports on Cell Expansion in related sectors.

Quick Read Table of Contents of this Report @ Cell Expansion Market 2020 and Forecast 2021-2027 Includes Business Impact Analysis of COVID-19

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

See original here:
Cell Expansion Market Analysis, COVID-19 Impact,Outlook, Opportunities, Size, Share Forecast and Supply Demand 2021-2027|Trusted Business Insights -...

University of Alberta research team poised to cure diabetesagain – The Post – Ontario

By Stem Cell Medicine

The team, led by Dr. James Shapiro, has been able to consistently cure diabetes in mice and is now looking to move to human trials

Published on: November 18, 2020 | Last Updated: November 18, 2020 10:56 AM EST

Dr. James Shapiro, a liver transplant surgeon with the University of Alberta and director of the Clinical Islet and Living Donor Liver Transplant programs with Alberta Health Services, inspects the OrganOx Metra portable ex-vitro perfusion device - the first of its kind in North America - at the University of Alberta Hospital on Wednesday, March 18, 2015. PHOTO BY CLAIRE THEOBALD/EDMONTON SUN.

Almost 20 years after a University of Alberta research group made medical history by improving on a treatment for diabetes, the same team is trying to do it again.

Dr. James Shapiro and his research team at the university say theyve been able to cure diabetes in mice, CTV Alberta reports. The team is using a technique that involves stem cells developing into pancreatic cells that can produce insulin. They believe their research can translate into a functional human cure for diabetes.

Weve been working with a company called ViaCyte in San Diego for the last, almost 19 years now, and this company has a cell that is derived from a human embryonic stem cell that makes human insulin in a regulated, perfect way, Dr. Shapiro said in video research update. Weve been able to treat countless thousands of mice with these stem cells and effectively cure mice with diabetes over many years now.

In the late 1990s, Dr. Shapiro and his team in Edmonton improved on the technique of transplanting insulin-producing islet cells from the pancreases of donors into type 1 diabetics. Their technique, which relies on using a large number of the islet cells from as many as three different donors, was published to The New England Journal of Medicinein 2000 and became known as the Edmonton protocol.

Unfortunately, islet cell implantation has major limitations. Transplant recipients are forced to take immunosuppressant anti-rejection drugs that come with a grocery list of side effects, such as high blood pressure and increased risk of infections. Then theres the lack of supply organ donations and the risk that, in most cases, the diabetic patient will slowly have to start reintegrating insulin over the years.

The stem cell therapy that Dr. Shapiro is proposing has none of these drawbacks. The University of Alberta team foresee a one-time injection with possible re-ups later on of insulin-producing cells derived from human stem cells. No need for immunosuppressants or organ donations.

Now, the team is ready to move on to human trials. The only obstacle: money. A small volunteer group, Heading to 2022, wants to raise $22 million by 2022 to help bring Dr. Shapiros new treatment to the next phase of trials.

2022 will be the 100th anniversary of the first successful insulin injection. In 1922, Dr. Frederick Banting and his small team, working out of the University of Toronto, saved the life of a 14-year-old-boy named Leonard Thompson, who was dying from diabetes.

Original post:
University of Alberta research team poised to cure diabetesagain - The Post - Ontario

Comprehensive Report on Stem Cell Assay Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Bio-Techne Corporation, Promega…

By Stem Cell Medicine

Stem Cell Assay Market research report is the new statistical data source added by A2Z Market Research.

Stem Cell Assay Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Stem Cell Assay Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=349580

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

Bio-Techne Corporation, Promega Corporation, Merck KGaA, STEMCELL Technologies, GE Healthcare, Thermo Fisher Scientific, Cellular Dynamics International, Bio-Rad Laboratories, Hemogenix, Cell Biolabs

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Stem Cell Assay market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Stem Cell Assay markets trajectory between forecast periods.

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=349580

Global Stem Cell Assay Market Segmentation:

Market Segmentation by Type:

Viability/Cytotoxicity Isolation & Purification Cell Identification Proliferation Differentiation Function Apoptosis

Market Segmentation by Application:

Regenerative Medicine & Therapy Development Drug Discovery and Development Clinical Research

Regions Covered in the Global Stem Cell Assay Market Report 2020: The Middle East and Africa(GCC Countries and Egypt) North America(the United States, Mexico, and Canada) South America(Brazil etc.) Europe(Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The report provides insights on the following pointers:

Table of Contents

Global Stem Cell Assay Market Research Report 2020 2026

Chapter 1 Stem Cell Assay Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Stem Cell Assay Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=349580

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

The rest is here:
Comprehensive Report on Stem Cell Assay Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Bio-Techne Corporation, Promega...

Asia Pacific ultra-low temperature freezer market is anticipated to reach US$ 159.04 million by 2027 from US$ 109.02 million in 2019 – GlobeNewswire

By Stem Cell Medicine

November 18, 2020 10:51 ET | Source: ReportLinker

New York, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Asia Pacific Ultra-Low Temperature Freezer Market to 2027 Regional Analysis and Forecasts by Type ; End User ; and, Country" - https://www.reportlinker.com/p05953753/?utm_source=GNW Growing R&D activities to introduce new drug compounds, is likely to damage the growth of the market in the coming years.

On the other hand, development in the healthcare market is expected to have a positive impact on the growth of the Asia Pacific ultra-low temperature freezer market in the coming years. Ultra-low temperature freezers are designed for storage of biological materials such as virus, bacteria, eukaryotic cells, blood, and semen. These freezers are used in blood banks, hospitals, epidemic prevention services, research institutes, and biomedical engineering facilities, among others. Pharmaceutical companies focus on R&D to introduce new molecules for various therapeutic applications with enhanced medical and commercial potential. The companies invest majorly on R&D activities with an aim to delivering high quality and innovative products in the market. R&D spending by biopharmaceutical companies has been increasing over the years. According to the report of Pharmaceutical Research and Manufacturers of America (PhRMA), the R&D expenditure of the biopharmaceutical companies has increased from US$ 49.6 billion in 2012 to US$ 58.8 billion in 2015. Among the worlds top 50 companies by total R&D investment in the fiscal year 2014/2015 were 16 pharmaceutical companies. Novartis, Roche, Johnson & Johnson, and Pfizer are among the top 10 leading R&D investing companies worldwide. Temperature accuracy and monitoring are the major aspects in medical science to preserve and store temperature-sensitive biomedical components that are frequently used for new drug development. Thus, the growing R&D expenditure to introduce new drug compounds will require reliable storage; this, in turn, is expected to drive the growth of the ultra-low temperature freezers market during the forecast period. As per the S&P Global ratings, the COVID-19 outbreak is expected to wipe approximately US$ 200 billion of Asia Pacific economies this year, sending growth rate to its lowest level.The outbreak has spread to at least 85 countries in the region and is expected to hamper the market growth as investors fret over its economic impact.

The total reported COVID-19 cases in the major countries of APAC are: china (82,295), Japan (8,100), and India (11,555).The pharmaceutical companies in the region are working on drug discovery and clinical testing processes on a large scale.

However, China and Japan have been frontiers in the research activities including the development of stem cell therapies, cell therapies, and regenerative medicine. Therefore, the ultra-low temperature freezer market in APAC is anticipated to be less affected by the pandemic situation. In terms of type, the upright ULT freezers segment accounted for the largest share of the Asia Pacific ultra-low temperature freezer market in 2019 and is estimated to mark the highest CAGR in the market during the forecast period, owing to the factors such as easier to organize because of having shelves. Also, the convenience of use of upright freezers has led to its dominance during 2019 and is expected to witness similar trend over the coming years. Centers for Disease Control and Prevention (CDC), Biomedical Research Centers (BRCs), Society of Infectious and Tropical Diseases (SIMIT), and International Society for Stem Cell Application (ISSCA) are among the significant primary and secondary sources for ultra-low temperature freezer included in the report. Read the full report: https://www.reportlinker.com/p05953753/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Lyon, FRANCE

Formats available:

View post:
Asia Pacific ultra-low temperature freezer market is anticipated to reach US$ 159.04 million by 2027 from US$ 109.02 million in 2019 - GlobeNewswire

→←